In premenopausal patients with ER + breast cancer, tumor growth can be decreased by reducing estrogen production via ovary removal, ovarian ablation, or the administration of a gonadotropin-releasing hormone agonist (GnRHa) [2]. This evidence concerns the gene ESR1 and breast carcinoma.